CHAPEL HILL, N.C., Feb. 23 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a
pharmaceutical development company with a portfolio of product candidates for
the treatment of migraine, today announced it plans to conduct a conference
call following the release of financial results for the fourth quarter and
year ended December 31, 2000. The company will release earnings before the
market opens on Thursday, March 1, 2001. John R. Plachetka, Pharm.D., POZEN's
president and chief executive officer, and Matthew Czajkowski, chief financial
officer, will host the conference call the same day at 11:00 a.m. Eastern
The conference call will be simulcast live on the Internet, and can be
accessed by logging on to http://www.streetevents.com . A replay will be
available at this sight, as well as on the Investor Relations section of the
company's website, http://www.pozen.com , for seven days.
North Carolina-based POZEN Inc. is a pharmaceutical development company
committed to building a portfolio of products with significant commercial
potential in select therapeutic areas. The company's initial focus is
migraine, where it has built a robust portfolio of four product candidates
through a combination of innovation and in-licensing. The company's common
stock is traded on The Nasdaq Stock Market under the symbol "POZN."
POZEN is on the Internet at http://www.pozen.com .
Chief Financial Officer, of POZEN
Kathy Brunson of FRB Weber Shandwick